Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

A Study of SYH2053 Injection in Participants With Hepatic Impairment Compared to Participants With Normal Hepatic Function

A Phase I Clinical Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of SYH2053 Injection in Participants With Mild Hepatic Impairment (Child-Pugh Class A), Moderate Hepatic Impairment (Child-Pugh Class B), and Normal Hepatic Function.

This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of SYH2053 injection in participants with mild, and moderate hepatic impairment compared to participants with normal hepatic function.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

24

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Clinical Trials Information Group NA officer
  • Telefonní číslo: 86-0311-69085587
  • E-mail: ctr-contact@cspc.cn

Studijní místa

    • Shandong
      • Jinan, Shandong, Čína, 250014
        • Nábor
        • the First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
        • Kontakt:
          • wei zhao Chief pharmacist, Pharmaciae Doctor
          • Telefonní číslo: CN 0531-89268212
          • E-mail: zhao4wei2@hotmail.com

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 75 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Aged between 18 and 75 years (inclusive), males or females.
  • Body weight ≥ 45.0 kg for females or ≥ 50.0 kg for males, and body mass index (BMI) between 18 and 32 kg/m² (inclusive), where BMI = weight (kg) / height² (m²).
  • LDL-C ≥ 70 mg/dL (1.8 mmol/L) at the screening visit.
  • Participants must be able to communicate well with the investigator and be willing and able to comply with all protocol requirements throughout the study.
  • For participants with hepatic impairment: patients with chronic hepatic impairment or cirrhosis caused by primary liver diseases (e.g., viral hepatitis, alcoholic liver disease, autoimmune hepatitis, etc.), classified as Child-Pugh Class A or B at screening; and judged by the investigator to have stable disease status for at least 1 month based on clinical presentation and other findings.
  • For participants with hepatic impairment: stable treatment for hepatic impairment, its complications, and other concomitant diseases for at least 1 month prior to study drug administration, with no anticipated dose adjustments needed during the study.
  • For participants with hepatic impairment: except for hepatic insufficiency and its complications, the subject's physical condition is deemed acceptable based on assessments of vital signs, physical examination, laboratory tests, 12-lead electrocardiogram, chest X-ray, ultrasound examination, and routine electroencephalogram.
  • For participants with normal hepatic function: subjects are matched to participants in the hepatic insufficiency group by body weight (within ±10 kg), age (within ±10 years), and sex, allowing a sex count difference of up to ±1 between the two groups.
  • For participants with normal hepatic function: physical examination, vital signs, laboratory tests, 12-lead electrocardiogram, chest X-ray, and ultrasound examination show results that are either normal or abnormal but without clinical significance.

Exclusion Criteria:

  • History of severe allergic reactions, including but not limited to anaphylactic shock and severe generalized urticaria, or documented hypersensitivity to oligonucleotide-based therapeutics.
  • Initiation of or unstable use of lipid-lowering agents, or drugs or supplements with lipid-modulating effects as determined by the investigator, within 30 days prior to screening, including but not limited to statins, fibrates, ezetimibe/hyzetimibe, red yeast rice, niacin, omega-3 fatty acids, stanols, or bile acid sequestrants; use of PCSK9 monoclonal antibodies or oral PCSK9 inhibitors within 180 days prior to screening; or use of Leqvio® (inclisiran) or any other RNA-based therapy for lipid-lowering purposes within 2 years prior to screening, including but not limited to siRNA or antisense oligonucleotide therapy.
  • Participation in any clinical trial and receipt of investigational drug within 5 half-lives of the study drug or within 90 days prior to screening (whichever is longer), or plan to participate in any other clinical trial during the study period.
  • Average daily smoking of more than 5 cigarettes (or equivalent tobacco in e-cigarettes) within 3 months prior to screening, and/or unwillingness to refrain from using any tobacco products during the study period.
  • Subjects with habitual alcohol use within 6 months prior to screening, defined as consumption of more than 14 units of alcohol per week (1 unit = 360 mL of beer [5% alcohol], 45 mL of spirits [40% alcohol], or 150 mL of wine [12% alcohol]); and/or those who are unable to refrain from alcohol consumption during the study period; and/or those with a positive breath alcohol test at screening.
  • History of drug abuse, and/or a positive urine drug screening test.
  • Daily consumption of excessive tea, coffee, and/or caffeinated beverages (8 cups or more per day, 1 cup = 250 mL) within 1 month prior to screening, and/or unwillingness to refrain from consuming tea, coffee, and/or caffeinated foods, grapefruit (pomelo) and/or grapefruit juice, and/or poppy seed-containing products during the study period.
  • Blood loss or blood donation exceeding 200 mL within 3 months prior to screening, and/or platelet donation within 2 weeks prior to screening, or planned blood donation during the study period.
  • Pregnant or lactating women; female participants of childbearing potential with a serum pregnancy test result exceeding the upper limit of normal at screening; or female participants who had unprotected sexual intercourse within 2 weeks prior to screening.
  • Planned pregnancy (including sperm donation or egg donation) from the signing of the informed consent form (ICF) until 6 months after study drug administration, and/or unwillingness to adopt effective non-pharmacological contraceptive methods.
  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for participation in this clinical trial.
  • For participants with hepatic impairment: active hepatitis B or hepatitis C at screening.
  • For participants with hepatic impairment: subjects who meet any of the following criteria at screening and/or baseline (if applicable) are excluded: a) Positive for HIV antibody or syphilis antibody; b) Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², calculated using the CKD-EPI formula; c) Glycated hemoglobin (HbA1c) > 8.5%; d) Systolic blood pressure (SBP) ≥ 160 mmHg or diastolic blood pressure (DBP) ≥ 100 mmHg; e) Platelet count < 20 × 10⁹/L; f) Hemoglobin < 80 g/L.
  • For participants with hepatic impairment: drug-induced liver injury; history of liver transplantation; hepatorenal syndrome.
  • For participants with hepatic impairment: acute hepatic injury from any cause within 2 months prior to screening.
  • For participants with hepatic impairment: severe ascites or pleural effusion requiring paracentesis or drainage.
  • For participants with hepatic impairment: diseases affecting bile excretion, such as biliary cirrhosis, biliary obstruction, or cholestatic liver disease.
  • For participants with hepatic impairment: severe portal hypertension or prior portosystemic shunt surgery, including transjugular intrahepatic portosystemic shunt (TIPS).
  • For participants with hepatic impairment: hepatic failure at screening, or cirrhosis complicated by hepatic encephalopathy, hepatocellular carcinoma, esophageal or gastric variceal bleeding, or other complications deemed unsuitable by the investigator.
  • For participants with hepatic impairment: any current or prior (within 24 weeks prior to screening) clinical disease involving the circulatory, endocrine, neuropsychiatric, digestive, respiratory, hematologic, or urinary systems that, in the investigator's assessment, makes the participant unsuitable for participation in the trial.
  • For participants with normal hepatic function: use of any medication within 14 days or 5 half-lives (whichever is longer) prior to dosing (with the exception of topical preparations exerting local effects).
  • For participants with normal hepatic function: positive for hepatitis B surface antigen, hepatitis C virus antibody, HIV antibody, or syphilis antibody.
  • For participants with normal hepatic function: any current or prior (within 24 weeks prior to screening) severe or chronic disease involving the circulatory, endocrine, neuropsychiatric, digestive, respiratory, hematologic, or urinary systems, or any other disease that may interfere with the trial results.
  • For participants with normal hepatic function: physical examination and/or laboratory findings at screening suggesting the presence or potential presence of hepatic impairment.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Nerandomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: SYH2053 (normal hepatic function)

SYH2053 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Experimentální: SYH2053 (mild hepatic function)

SYH2053 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Experimentální: SYH2053 (moderate hepatic function)

SYH2053 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Časové okno
Amount excreted unchanged in urine (Ae) of SYH2053 over 72 hours post-dose
Časové okno: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Fraction excreted (fe) of SYH2053 over 72 hours post-dose
Časové okno: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Renal clearance (CLr) of SYH2053
Časové okno: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Maximum observed plasma concentration (Cmax)
Časové okno: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Area under the curve of the plasma concentration (AUC) from time 0 to the last measurable time (AUC0-t) and from time 0 extrapolated to infinity (AUC0-inf)
Časové okno: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Time to reach maximum plasma concentration (Tmax) and terminal half-life (t1/2).
Časové okno: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Pharmacokinetics: Apparent total clearance (CL/F)
Časové okno: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Pharmacokinetics: Apparent volume of distribution (Vz/F)
Časové okno: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
The serum Low-density lipoprotein cholesterol (LDL-C) level
Časové okno: 6 months
6 months
The serum PCSK9 level
Časové okno: 6 months
6 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

15. srpna 2026

Primární dokončení (Odhadovaný)

15. srpna 2027

Dokončení studie (Odhadovaný)

15. září 2027

Termíny zápisu do studia

První předloženo

11. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

11. listopadu 2026

První zveřejněno (Aktuální)

17. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

17. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

11. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • SYH2053-008

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .